Geriatric depression is a heterogeneous disorder that increases morbidity and mortality in a population that is already vulnerable. Predicting response and remission to antidepressants could help clinicians to optimize the management of antidepressants and reduce the consequences of depression.
Method:
The aim of this article is to present results of a systematic review of the literature on predictive factors related to antidepressant response and remission in older adults with depression.
Main Findings:
We identified sociodemographic, clinical, neuropsychological, neuroimaging, and genetic factors that could be potential predictors of outcomes. Inconsistent findings and methodological differences among studies, however, limit the generalizability and application of these predictors in clinical practice. The results of our review confirm that geriatric depression includes many subgroups of patients with particular endophenotypes that may influence the course of depression.
Conclusion:
Further studies are needed to characterize depression subgroups in order to better understand the pathophysiology of late life depression and to find specific predictors for each group of patients.
BostwickJMPankratzVS. Affective disorders and suicide risk: a reexamination. Am J Psychiatry. 2000;157(12):1925–1932. doi:10.1176/appi.ajp.157.12.1925.
2.
KesslerRCChiuWTDemlerOMerikangasKRWaltersEE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry. 2005;62(6):617–627. doi:10.1001/archpsyc.62.6.617.
3.
HybelsCFBlazerDG. Epidemiology of late-life mental disorders. Clin Geriatr Med. 2003;19(4):663–696, v.
4.
BlazerDHughesDCGeorgeLK. The epidemiology of depression in an elderly community population. Gerontologist. 1987;27(3):281–287. doi:10.1093/geront/27.3.281.
5.
SaveanuREtkinADucheminA-M. The International Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment. J Psychiatr Res. 2015;61:1–12.
6.
FavaMRushAJAlpertJE. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D Report. Am J Psychiatry. 2008;165(3):342–351. doi:10.1176/appi.ajp.2007.06111868.
7.
TaylorBPBruderGEStewartJW. Psychomotor slowing as a predictor of fluoxetine nonresponse in depressed outpatients. Am J Psychiatry. 2006;163(1):73–78. doi:10.1176/appi.ajp.163.1.73.
GorlynMKeilpJGGrunebaumMF. Neuropsychological characteristics as predictors of SSRI treatment response in depressed subjects. J Neural Transm Vienna Austria 1996. 2008;115(8):1213–1219. doi:10.1007/s00702-008-0084-x.
10.
UherRTanseyKEDewT. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12):1278–1286. doi:10.1176/appi.ajp.2014.14010094.
11.
ChiKFKorgaonkarMGrieveSM. Imaging predictors of remission to anti-depressant medications in major depressive disorder. J Affect Disord. 2015;186:134–144. doi:10.1016/j.jad.2015.07.002.
12.
PorcelliSFabbriCSerrettiA. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4):239–258. doi:10.1016/j.euroneuro.2011.10.003.
13.
VoegeliGCléry-MelinMLRamozNGorwoodP. Progress in elucidating biomarkers of antidepressant pharmacological treatment response: a systematic review and meta-analysis of the last 15 years. Drugs. 2017;77(18):1967–1986. doi:10.1007/s40265-017-0819-9.
14.
TunvirachaisakulCGouldRLCoulsonMC. Predictors of treatment outcome in depression in later life: a systematic review and meta-analysis. J Affect Disord. 2018;227:164–182. doi:10.1016/j.jad.2017.10.008.
15.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–1012. doi:10.1016/j.jclinepi.2009.06.005.
16.
KarpJFFrankEAndersonB. Time to remission in late-life depression: analysis of effects of demographic, treatment, and life-events measures. Depression. 1993;1(5):250–256.
17.
DewMAReynoldsCFHouckPR. Temporal profiles of the course of depression during treatment: predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry. 1997;54(11):1016–1024.
18.
BosworthHBMcQuoidDRGeorgeLKSteffensDC. Time-to-remission from geriatric depression: psychosocial and clinical factors. Am J Geriatr Psychiatry. 2002;10(5):551–559.
19.
SteffensDCPieperCFBosworthHB. Biological and social predictors of long-term geriatric depression outcome. Int Psychogeriatr. 2005;17(1):41–56.
20.
LynessJMChapmanBPMcGriffJDrayerRDubersteinPR. One-year outcomes of minor and subsyndromal depression in older primary care patients. Int Psychogeriatr. 2009;21(1):60–68.
21.
LenzeEJMillerMDDewMA. Subjective health measures and acute treatment outcomes in geriatric depression. Int J Geriatr Psychiatry. 2001;16(12):1149–1155.
22.
SmagulaSFButtersMAAndersonSJ. Antidepressant response trajectories and associated clinical prognostic factors among older adults. JAMA Psychiatry. 2015;72(10):1021–1028.
23.
ShiromaPRThurasPJohnsBLimKO. Emotion recognition processing as early predictor of response to 8-week citalopram treatment in late-life depression. Int J Geriatr Psychiatry. 2014;29(11):1132–1139. doi:10.1002/gps.4104.
24.
Zilcha-ManoSRooseSPBrownPJRutherfordBR. Early symptom trajectories as predictors of treatment outcome for citalopram versus placebo. Am J Geriatr Psychiatry. 2017;25(6):654–661. doi:10.1016/j.jagp.2017.02.001.
25.
BosworthHBVoilsCIPotterGGSteffensDC. The effects of antidepressant medication adherence as well as psychosocial and clinical factors on depression outcome among older adults. Int J Geriatr Psychiatry. 2008;23(2):129–134.
26.
SoaresCNFayyadRSGuico-PabiaCJ. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2014;34(1):57–65.
27.
AlexopoulosGSMeyersBSYoungRC. Recovery in geriatric depression. Arch Gen Psychiatry. 1996;53(4):305–312.
28.
SullivanMDKatonWJRussoJE. Patient beliefs predict response to paroxetine among primary care patients with dysthymia and minor depression. J Am Board Fam Pract. 2003;16(1):22–31.
29.
AndreescuCMulsantBHHouckPR. Empirically derived decision trees for the treatment of late-life depression. Am J Psychiatry. 2008;165(7):855–862.
30.
GeorgotasAMcCueRECooperTChangIMirPWelkowitzJ. Clinical predictors of response to antidepressants in elderly patients. Biol Psychiatry. 1987;22(6):733–740.
31.
SmallGWHamiltonSHBystritskyAMeyersBSNemeroffCB. Clinical response predictors in a double-blind, placebo-controlled trial of fluoxetine for geriatric major depression. Int Psychogeriatr. 1995;7(S1):41–53.
32.
DeligiannidisKMRothschildAJBartonBA. A gender analysis of the Study of the Pharmacotherapy of Psychotic Depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures. J Clin Psychiatry. 2013;74(10):1003.
33.
NelsonJCHoldenKRooseSSalzmanCHollanderSBBetzelJV. Are there predictors of outcome in depressed elderly nursing home residents during treatment with mirtazapine orally disintegrating tablets?Int J Geriatr Psychiatry. 2007;22(10):999–1003.
34.
FriedmanESDavisLLZisookS. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol. 2012;22(3):183–199.
35.
RosenthalMZCheavensJSComptonJSThorpSRLynchTR. Thought suppression and treatment outcome in late-life depression. Aging Ment Health. 2005;9(1):35–39.
36.
JoelIBegleyAEMulsantBH. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry. 2014;22(2):167–176.
37.
Licht-StrunkEVan MarwijkHWJHoekstraTTwiskJWRDe HaanMBeekmanATF. Outcome of depression in later life in primary care: longitudinal cohort study with three years’ follow-up. BMJ. 2009;338:a3079.
38.
JarvikLFMintzJSTEUERJGernerR. Treating geriatric depression: a 26-week interim analysis. J Am Geriatr Soc. 1982;30(11):713–717.
39.
VolzH-PMüllerHSturmYPreuβlerBMöllerH-J. Effect of initial treatment with antidepressants as a predictor of outcome after 8 weeks. Psychiatry Res. 1995;58(2):107–115.
40.
AckermanDLGreenlandSBystritskyASmallGW. Side effects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol. 2000;20(6):658–665.
41.
CohenAGilmanSEHouckPRSzantoKReynoldsCF. Socioeconomic status and anxiety as predictors of antidepressant treatment response and suicidal ideation in older adults. Soc Psychiatry Psychiatr Epidemiol. 2009;44(4):272.
42.
KaneriyaSHRobbins-WeltyGASmagulaSF. Predictors and moderators of remission with aripiprazole augmentation in treatment-resistant late-life depression: an analysis of the IRL-GRey randomized clinical trial. JAMA Psychiatry. 2016;73(4):329–336.
43.
StekMLExelEVTilburgWVWestendorpRGJBeekmanATF. The prognosis of depression in old age: outcome six to eight years after clinical treatment. Aging Ment Health. 2002;6(3):282–285.
44.
SmallGWBirkettMMeyersBSKoranLMBystritskyANemeroffCB. Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. J Am Geriatr Soc. 1996;44(10):1220–1225.
45.
MillerMDSchulzRParadisC. Changes in perceived health status of depressed elderly patients treated until remission. Am J Psychiatry. 1996;153(10):1350–1352. doi:10.1176/ajp.153.10.1350.
46.
HernandezCRSmithGSHouckPR. The clinical response to total sleep deprivation and recovery sleep in geriatric depression: potential indicators of antidepressant treatment outcome. Psychiatry Res. 2000;97(1):41–49.
47.
AlexopoulosGSKanellopoulosDMurphyCGunning-DixonFKatzRHeoM. Placebo response and antidepressant response. Am J Geriatr Psychiatry. 2007;15(2):149–158. doi:10.1097/01.JGP.0000232206.91841.d9.
48.
ComijsHCJonkerCBeekmanATDeegDJ. The association between depressive symptoms and cognitive decline in community-dwelling elderly persons. Int J Geriatr Psychiatry. 2001;16(4):361–367.
49.
ShelineYIBarchDMGarciaK. Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed. Biol Psychiatry. 2006;60(1):58–65. doi:10.1016/j.biopsych.2005.09.019.
50.
ShelineYIPieperCFBarchDM. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry. 2010;67(3):277–285. doi:10.1001/archgenpsychiatry.2009.204.
51.
KalayamBAlexopoulosGS. Prefrontal dysfunction and treatment response in geriatric depression. Arch Gen Psychiatry. 1999;56(8):713–718.
52.
SimpsonSBaldwinRCJacksonABurnsAS. Is subcortical disease associated with a poor response to antidepressants? Neurological, neuropsychological and neuroradiological findings in late-life depression. Psychol Med. 1998;28(5):1015–1026.
53.
PotterGGKittingerJDWagnerHRSteffensDCKrishnanKRR. Prefrontal neuropsychological predictors of treatment remission in late-life depression. Neuropsychopharmacology. 2004;29(12):2266–2271. doi:10.1038/sj.npp.1300551.
54.
ShelineYIDisabatoBMHranilovichJ. Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry. 2012;169(11):1185–1193. doi:10.1176/appi.ajp.2012.12010122.
55.
SneedJRCulang-ReinliebMEBrickmanAM. MRI signal hyperintensities and failure to remit following antidepressant treatment. J Affect Disord. 2011;135(1-3):315–320. doi:10.1016/j.jad.2011.06.052.
56.
SallowaySCorreiaSBoyleP. MRI subcortical hyperintensities in old and very old depressed outpatients: the important role of age in late-life depression. J Neurol Sci. 2002;203-204:227–233.
57.
JanssenJHulshoff PolHESchnackHG. Cerebral volume measurements and subcortical white matter lesions and short-term treatment response in late life depression. Int J Geriatr Psychiatry. 2007;22(5):468–474. doi:10.1002/gps.1790.
58.
AlexopoulosGSHoptmanMJKanellopoulosDMurphyCFLimKOGunningFM. Functional connectivity in the cognitive control network and the default mode network in late-life depression. J Affect Disord. 2012;139(1):56–65. doi:10.1016/j.jad.2011.12.002.
59.
Gunning-DixonFMWaltonMChengJ. MRI signal hyperintensities and treatment remission of geriatric depression. J Affect Disord. 2010;126(3):395–401. doi:10.1016/j.jad.2010.04.004.
60.
KhalafAEdelmanKTudorascuDAndreescuCReynoldsCFAizensteinH. White matter hyperintensity accumulation during treatment of late-life depression. Neuropsychopharmacology. 2015;40(13):3027.
61.
HsiehM-HMcQuoidDRLevyRMPayneMEMacFallJRSteffensDC. Hippocampal volume and antidepressant response in geriatric depression. Int J Geriatr Psychiatry. 2002;17(6):519–525. doi:10.1002/gps.611.
62.
RibeizSRIDuranFOliveiraMC. Structural brain changes as biomarkers and outcome predictors in patients with late-life depression: a cross-sectional and prospective study. PLoS One. 2013;8(11):e80049. doi:10.1371/journal.pone.0080049.
63.
GunningFMChengJMurphyCF. Anterior cingulate cortical volumes and treatment remission of geriatric depression. Int J Geriatr Psychiatry. 2009;24(8):829–836. doi:10.1002/gps.2290.
64.
AlexopoulosGSKiossesDNChoiSJMurphyCFLimKO. Frontal white matter microstructure and treatment response of late-life depression: a preliminary study. Am J Psychiatry. 2002;159(11):1929–1932. doi:10.1176/appi.ajp.159.11.1929.
65.
AlexopoulosGSMurphyCFGunning-DixonFM. Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry. 2008;165(2):238–244. doi:10.1176/appi.ajp.2007.07050744.
66.
TaylorWDKuchibhatlaMPayneME. Frontal white matter anisotropy and antidepressant remission in late-life depression. PLoS One. 2008;3(9):e3267. doi:10.1371/journal.pone.0003267.
67.
AndreescuCTudorascuDLButtersMA. Resting state functional connectivity and treatment response in late-life depression. Psychiatry Res. 2013;214(3):313–321. doi:10.1016/j.pscychresns.2013.08.007.
68.
SmithGSReynoldsIII CFHouckPR. Glucose metabolic response to total sleep deprivation, recovery sleep, and acute antidepressant treatment as functional neuroanatomic correlates of treatment outcome in geriatric depression. Am J Geriatr Psychiatry. 2002;10(5):561–567.
69.
SmithGSKahnASacherJ. Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression. Am J Geriatr Psychiatry. 2011;19(12):1016–1025. doi:10.1097/JGP.0b013e318227f83f.
70.
MaranoCMWorkmanCIKramerE. Longitudinal studies of cerebral glucose metabolism in late-life depression and normal aging. Int J Geriatr Psychiatry. 2013;28(4):417–423. doi:10.1002/gps.3840.
71.
AlpertMSilvaRRPougetER. Prediction of treatment response in geriatric depression from baseline folate level: interaction with an SSRI or a tricyclic antidepressant. J Clin Psychopharmacol. 2003;23(3):309–313. doi:10.1097/01.jcp.0000084024.22282.cd.
72.
PaeC-UMandelliLKimT-S. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother. 2009;63(3):228–235.
73.
SparJELaRueA. Major depression in the elderly: DSM-III criteria and the dexamethasone suppression test as predictors of treatment response. Am J Psychiatry. 1983;140(7):844–847.
74.
MischoulonDRaabMF. The role of folate in depression and dementia. J Clin Psychiatry. 2007;68(suppl 10):28–33.
75.
AlpertJEFavaM. Nutrition and depression: the role of folate. Nutr Rev. 1997;55(5):145–149.
76.
AlexopoulosGSGlattCEHoptmanMJ. BDNF val66met polymorphism, white matter abnormalities and remission of geriatric depression. J Affect Disord. 2010;125(1-3):262–268. doi:10.1016/j.jad.2010.02.115.
77.
LavretskyHSiddarthPKumarAReynoldsCF. The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. Int J Geriatr Psychiatry. 2008;23(1):55–59. doi:10.1002/gps.1837.
78.
EyreHAEskinANelsonSF. Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study. Int J Geriatr Psychiatry. 2016;31(5):510–517. doi:10.1002/gps.4356.
79.
MarsheVSMaciukiewiczMRejS. Norepinephrine transporter gene variants and remission from depression with venlafaxine treatment in older adults. Am J Psychiatry. 2017;174(5):468–475. doi:10.1176/appi.ajp.2016.16050617.
80.
NewsomJTSchulzR. Social support as a mediator in the relation between functional status and quality of life in older adults. Psychol Aging. 1996;11(1):34–44.
81.
SeemanTEBruceMLMcAvayGJ. Social network characteristics and onset of ADL disability: MacArthur studies of successful aging. J Gerontol B Psychol Sci Soc Sci. 1996;51(4):S191–S200.
82.
BélangerEAhmedTVafaeiACurcioCLPhillipsSPZunzuneguiMV. Sources of social support associated with health and quality of life: a cross-sectional study among Canadian and Latin American older adults. BMJ Open. 2016;6(6):e011503. doi:10.1136/bmjopen-2016-011503.
83.
CacioppoSCapitanioJPCacioppoJT. Toward a neurology of loneliness. Psychol Bull. 2014;140(6):1464–1504. doi:10.1037/a0037618.
84.
CacioppoJTHawkleyLC. Perceived social isolation and cognition. Trends Cogn Sci. 2009;13(10):447–454. doi:10.1016/j.tics.2009.06.005.
85.
MasiCMChenH-YHawkleyLCCacioppoJT. A meta-analysis of interventions to reduce loneliness. Personal Soc Psychol Rev. 2011;15(3):219–266. doi:10.1177/1088868310377394.
86.
BennabiDAouizerateBEl-HageW. Risk factors for treatment resistance in unipolar depression: a systematic review. J Affect Disord. 2015;171:137–141.
87.
BalestriMCalatiRSoueryD. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord. 2016;189:224–232.
88.
FunesCMLavretskyHErcoliLSt. CyrNSiddarthP. Apathy mediates cognitive difficulties in geriatric depression. Am J Geriatr Psychiatry. 2018;26(1):100–106. doi:10.1016/j.jagp.2017.06.012.
89.
HardySE. Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother. 2009;7(1):34–59. doi:10.1016/j.amjopharm.2009.02.006.
90.
PadalaPRPettyFBhatiaSC. Methylphenidate may treat apathy independent of depression. Ann Pharmacother. 2005;39(11):1947–1949.
91.
CorcoranCWongMLO’KeaneV. Bupropion in the management of apathy. J Psychopharmacol (Oxf). 2004;18(1):133–135.
92.
ThomasAJKalariaRNO’BrienJT. Depression and vascular disease: what is the relationship?J Affect Disord. 2004;79(1):81–95. doi:10.1016/S0165-0327(02)00349-X.
93.
FranceschiCBonafèMValensinS. Inflamm-aging: an evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2006;908(1):244–254. doi:10.1111/j.1749-6632.2000.tb06651.x.
94.
Harris EyrePSCyrNYangHColeSForbesMLavretskyH. Comparing the immune-genomic effects of vilazodone and paroxetine in late-life depression: a pilot study. Pharmacopsychiatry. 2017;50(6):256.
95.
HannestadJDellaGioiaNBlochM. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36(12):2452–2459. doi:10.1038/npp.2011.132.
96.
EyreHALavretskyHKartikaJQassimABauneBT. Modulatory effects of antidepressant classes on the innate and adaptive immune system in depression. Pharmacopsychiatry. 2016;49(3):85–96. doi:10.1055/s-0042-103159.
97.
TaylorWDAizensteinHJAlexopoulosGS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–974. doi:10.1038/mp.2013.20.
98.
ThomasAJO’BrienJTBarberRMcMeekinWPerryR. A neuropathological study of periventricular white matter hyperintensities in major depression. J Affect Disord. 2003;76(1-3):49–54.
99.
AizensteinHJButtersMAWuM. Altered functioning of the executive control circuit in late-life depression: episodic and persistent phenomena. Am J Geriatr Psychiatry. 2009;17(1):30–42. doi:10.1097/JGP.0b013e31817b60af.
100.
ShelineYIBarchDMPriceJL. The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A. 2009;106(6):1942–1947. doi:10.1073/pnas.0812686106.
101.
FernandesBSWilliamsLMSteinerJLeboyerMCarvalhoAFBerkM. The new field of “precision psychiatry.”BMC Med. 2017;15(1):80. doi:10.1186/s12916-017-0849-x.
102.
AbbottRChangDDEyreHABousmanCAMerrillDALavretskyH. Pharmacogenetic decision support tools: a new paradigm for late-life depression?Am J Geriatr Psychiatry. 2018;26(2):125–133. doi:10.1016/j.jagp.2017.05.012.
